Gina Mauro

Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/

Investigators reported an objective response rate of 73% for the anti–B-cell maturation antigen teclistamab in patients with relapsed/ refractory multiple myeloma, according to results from an ongoing study.

Infection mortality rate were lower in patients with multiple myeloma who were coronavirus disease 2019 positive and received maintenance lenalidomide than those who did not receive lenalidomide, according to study results presented during the 2nd European Myeloma Network Meeting.

In preclinical models of acute myeloid leukemia with FLT3 internal tandem duplication mutation, AMG 176 in combination with gilteritinib demonstrated the ability to synergistically target the disease.

In preclinical models of KRAS-mutant cancer, voruciclib, a CDK9 inhibitor, showed early activity as monotherapy and when used in combination with sotorasib and adagrasib, according to findings presented during Week 1 of the 2021 AACR Annual Meeting.

Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Data presented during the 2021 Transplantation and Cellular Therapy Meetings showed that treatment with Orca-T achieved a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, and a lack of treatment-related mortalities while demonstrating scalability potential.

Progression-free survival and overall survival were improved with pembrolizumab and lenvatinib when compared with chemotherapy in patients with advanced endometrial cancer who had received prior platinum-based chemotherapy in the phase 3 Study-309/KEYNOTE-775 trial.

In patient with metastatic renal cell carcinoma who have brain metastases, treatment with cabozantinib displayed significant intracranial and extracranial, results from a retrospective analysis presented during the 2021 Genitourinary Cancers Symposium show.

Data presented during the 2021 Transplantation and Cellular Therapy Meeting showed that treatment with Orca-T, achieved a significant reduction in cases of graft-versus-host disease and other impressive outcomes.

A subgroup analysis from the phase 3 JAVELIN Bladder 100 trial demonstrated that Japanese patients with advanced urothelial cancer whose disease did not progress on frontline chemotherapy benefited from the addition of avelumab to best supportive care in the first-line maintenance setting.

In a pivotal phase 2 trial, administration of narsoplimab to patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy led to impressive responses and a favorable survival benefit.

Survival was not improved with the immunotherapy combination of pembrolizumab and ipilimumab in comparison with pembrolizumab monotherapy in the first-line treatment of patients with metastatic non–small cell lung cancer who had high PD-L1 expression and did not harbor EGFR or ALK aberrations, findings from the phase 3 KEYNOTE-598 trial showed.

Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer, according to results from the phase 2 portion of the CodeBreaK 100 trial to be presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer.

Larger, retrospectives studies are needed after NRG1 fusions were detected in patients with non-small cell lung cancer.

In the phase 2 JACCRO GC-07 trial, patients with stage III gastric cancer who received the combination of S-1 and docetaxel in the adjuvant setting had a 29% reduction in the risk of relapse.

The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets achieved a 21% reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo.

In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.

Neratinib in combination with capecitabine induced a 34% reduction in the risk of disease progression or death as treatment of patients with HER2-positive breast cancer who had central nervous system metastases at baseline compared with lapatinib and capecitabine.

In the phase 3 PROTECTIVE-2 trial, patient with breast cancer who received plinabulin and pegfilgrastim experienced a reduction in the incidence of profound neutropenia that was 53% more effective than that of chemotherapy, according to findings presented during the 2020 San Antonio Breast Cancer Symposium.

The GP2 immunotherapy in combination with granulocyte-macrophage colony-stimulating factor induced a 100% disease-free survival with potent responses as treatment of patients with HER2/neu 3–positive disease who received adjuvant trastuzumab .

Treatment with amcenestrant demonstrated antitumor activity in postmenopausal women with heavily pretreated advanced or metastatic estrogen receptor–positive breast cancer.

Patients with HER2-positive metastatic breast cancer treated with fam-trastuzumab deruxtecan-nxki had continued to experience extended durable responses and overall survival rates, along with tolerable toxicity in the phase 2 DESTINY-Breast01 study for which data were presented during the 2020 San Antonio Breast Cancer Symposium.

In the phase 3 KX-ORAX-001 clinical trial, treatment with paclitaxel in combination with encequidar achieved a 26.5% reduction in the risk of death compared with paclitaxel by intravenous injection in patients with metastatic breast cancer.

Invasive disease-free survival was prolonged in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer treated with abemaciclib in combination with standard endocrine therapy in the phase 3 monarchE trial, according to a presentation at the 2020 San Antonio Breast Cancer Symposium.

A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.

A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration leads to high, durable, and consistent responses in patients with follicular lymphoma across multiple subgroups. Data from the study were presented during the virtual 2020 American Society of Hematology Annual Meeting.

Treatment with asciminib led to an almost doubling of the major molecular response rate compared with bosutinib at 24 weeks in patients with chronic-phase chronic myeloid leukemia.

A 20-mg 3-times-weekly or twice-weekly dosing schedule of panobinostat combined with subcutaneous bortezomib plus dexamethasone induced durable responses as treatment of patients with relapsed or refractory multiple myeloma and demonstrated an acceptable safety profile in the phase 2 PANORAMA 3 study.

Promising antitumor activity, as well as an acceptable safety profile, continues to be demonstrated with odronextamab, a novel CD20xCD3 bispecific antibody, as treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.